RAFA Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -- compared to Rafarma Pharmaceuticals, Inc.'s net margin of --. Rafarma Pharmaceuticals, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.

Rafarma Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that NanoViricides, Inc. has higher upside potential than Rafarma Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Rafarma Pharmaceuticals, Inc..

Rafarma Pharmaceuticals, Inc. has a beta of 0.502, which suggesting that the stock is 49.826% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Rafarma Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Rafarma Pharmaceuticals, Inc.'s net income of -- is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Rafarma Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.12x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals, Inc. is 0.29x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -- compared to Rafarma Pharmaceuticals, Inc.'s net margin of --. Rafarma Pharmaceuticals, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.

Rafarma Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that Oragenics, Inc. has higher upside potential than Rafarma Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Rafarma Pharmaceuticals, Inc..

Rafarma Pharmaceuticals, Inc. has a beta of 0.502, which suggesting that the stock is 49.826% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Rafarma Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Rafarma Pharmaceuticals, Inc.'s net income of -- is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Rafarma Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.12x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals, Inc. is 0.29x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Rafarma Pharmaceuticals, Inc.'s net margin of --. Rafarma Pharmaceuticals, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Rafarma Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Rafarma Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Rafarma Pharmaceuticals, Inc..

Rafarma Pharmaceuticals, Inc. has a beta of 0.502, which suggesting that the stock is 49.826% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Rafarma Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Rafarma Pharmaceuticals, Inc.'s net income of -- is lower than Palatin Technologies's net income of --. Notably, Rafarma Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.12x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals, Inc. is 0.29x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Rafarma Pharmaceuticals, Inc.'s net margin of --. Rafarma Pharmaceuticals, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Rafarma Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Theriva Biologics, Inc. has higher upside potential than Rafarma Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Rafarma Pharmaceuticals, Inc..

Rafarma Pharmaceuticals, Inc. has a beta of 0.502, which suggesting that the stock is 49.826% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Rafarma Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Rafarma Pharmaceuticals, Inc.'s net income of -- is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Rafarma Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.12x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals, Inc. is 0.29x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.